Ascendis Pharma A/S (NASDAQ:ASND) Short Interest Down 13.1% in July

Ascendis Pharma A/S (NASDAQ:ASND) was the recipient of a significant decline in short interest during the month of July. As of July 15th, there was short interest totalling 1,660,000 shares, a decline of 13.1% from the June 30th total of 1,910,000 shares. Based on an average daily volume of 239,200 shares, the days-to-cover ratio is presently 6.9 days. Currently, 3.7% of the company’s stock are short sold.

Several large investors have recently added to or reduced their stakes in ASND. Vivo Capital LLC acquired a new position in shares of Ascendis Pharma A/S in the first quarter valued at approximately $225,574,000. RA Capital Management L.P. increased its holdings in shares of Ascendis Pharma A/S by 17.4% in the first quarter. RA Capital Management L.P. now owns 4,914,955 shares of the biotechnology company’s stock valued at $553,473,000 after purchasing an additional 729,613 shares during the period. Janus Henderson Group PLC increased its holdings in shares of Ascendis Pharma A/S by 49.0% in the first quarter. Janus Henderson Group PLC now owns 1,867,190 shares of the biotechnology company’s stock valued at $210,264,000 after purchasing an additional 614,186 shares during the period. Bank of New York Mellon Corp acquired a new position in shares of Ascendis Pharma A/S in the fourth quarter valued at approximately $18,658,000. Finally, Spyglass Capital Management LLC increased its holdings in shares of Ascendis Pharma A/S by 40.0% in the first quarter. Spyglass Capital Management LLC now owns 351,388 shares of the biotechnology company’s stock valued at $39,570,000 after purchasing an additional 100,416 shares during the period.

Shares of NASDAQ ASND opened at $137.61 on Friday. The company has a current ratio of 13.19, a quick ratio of 13.19 and a debt-to-equity ratio of 0.06. Ascendis Pharma A/S has a twelve month low of $90.06 and a twelve month high of $158.93. The stock has a 50 day moving average of $143.81 and a two-hundred day moving average of $134.83. The stock has a market cap of $7.27 billion, a P/E ratio of -25.82 and a beta of 0.98.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings data on Tuesday, May 19th. The biotechnology company reported ($1.32) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.43) by $0.11. Ascendis Pharma A/S had a negative return on equity of 36.56% and a negative net margin of 2,231.94%. The company had revenue of $2.45 million during the quarter, compared to analysts’ expectations of $2.66 million. As a group, research analysts predict that Ascendis Pharma A/S will post -6.47 earnings per share for the current year.

Several equities research analysts recently weighed in on the company. SVB Leerink boosted their target price on Ascendis Pharma A/S from $170.00 to $173.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 20th. BidaskClub upgraded Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, July 22nd. Canaccord Genuity boosted their target price on Ascendis Pharma A/S from $166.00 to $170.00 and gave the stock a “buy” rating in a research note on Monday, April 20th. Oppenheimer decreased their target price on Ascendis Pharma A/S from $219.00 to $208.00 and set an “outperform” rating for the company in a research note on Wednesday, May 20th. Finally, Morgan Stanley decreased their target price on Ascendis Pharma A/S from $181.00 to $177.00 and set an “overweight” rating for the company in a research note on Wednesday, July 15th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $168.17.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Further Reading: What sectors are represented in the Hang Seng index?

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.